Advertisement FDA grants approval to Strides Doxorubicin Hydrochloride injection - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA grants approval to Strides Doxorubicin Hydrochloride injection

The US FDA has granted approval to Onco Therapies, a subsidiary of Strides Arcolab, an Indian pharmaceutical company, to market its Doxorubicin Hydrochloride injection in the US market.

The injection is indicated to treat cancer and is administered intravenously, hindubusinessline.com reported.

The drug in the strengths of 10 mg/ vial and 50 mg/ vial, received approval

The Hindu Business Line quoted Strides Arcolab as saying that the drug belongs to the oncology portfolio licensed to Pfizer in January 2010 for the US market.